Biotechnology startup Moonwalk Biosciences has raised $57 million in venture capital and joined a push to treat diseases through drugs that activate or suppress genes.
Proponents say this new twist on genetic medicine, “epigenetic editing,” promises to lead to treatments or cures for a variety of common medical scourges, such as cancer and chronic hepatitis B.
Copyright ©2024 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
